EYEG - Investors Should Be Excited For EyeGate's Ocular Bandage
Image Source: OPIS
Company Thesis
EyeGate's (EYEG) recent Phase 3 interim data release on its lead candidate, Ocular Bandage Gel, demonstrated significant evidence favoring the drug's approval. Its formulation as an eye drop instead of a contact lens should also aid in sales and marketing efforts towards ophthalmologists. However, OBG's designation as a non-essential treatment combined with a limited total addressable market for corneal healing post refractive surgery casts a shadow on its clinical trial success. Furthermore, the company's burn rate guarantees a modest stock dilution in the near term. Despite this, the